225 related articles for article (PubMed ID: 33331182)
1. A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
Li Y; Yin Y; Peng X; Zheng H; Fu F; Liu Z; Wu X; Wu X; Zheng S; Chen N; He L; Ren L; Ni Z; Li D; Liang P; Lv X; Zhang Y
Ann Med; 2021 Dec; 53(1):217-226. PubMed ID: 33331182
[TBL] [Abstract][Full Text] [Related]
2. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial.
Lyu J; Xie YM; Gao Z; Shen JW; Deng YY; Xiang ST; Gao WX; Zeng WT; Zhang CH; Yi DH; Wang LX; Wang ZF
Trials; 2019 Jul; 20(1):446. PubMed ID: 31324199
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia.
Li Y; Zhu D; Peng Y; Tong Z; Ma Z; Xu J; Sun S; Tang H; Xiu Q; Liang Y; Wang X; Lv X; Dai Y; Zhu Y; Qu Y; Xu K; Huang Y; Wu S; Lai G; Li X; Han X; Yang Z; Sheng J; Liu Z; Li H; Chen Y; Zhu H; Zhang Y
Curr Med Res Opin; 2021 Apr; 37(4):693-701. PubMed ID: 33534617
[TBL] [Abstract][Full Text] [Related]
4. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.
Henry DC; Bettis RB; Riffer E; Haverstock DC; Kowalsky SF; Manning K; Hamed KA; Church DA
Clin Ther; 2002 Dec; 24(12):2088-104. PubMed ID: 12581547
[TBL] [Abstract][Full Text] [Related]
5. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
6. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
Kohno S; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Fujita J; Tanigawara Y
J Infect Chemother; 2013 Jun; 19(3):486-94. PubMed ID: 23525983
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
[TBL] [Abstract][Full Text] [Related]
8. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Dawe RS; Ibbotson SH; Sanderson JB; Thomson EM; Ferguson J
Br J Dermatol; 2003 Dec; 149(6):1232-41. PubMed ID: 14674902
[TBL] [Abstract][Full Text] [Related]
10. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
[TBL] [Abstract][Full Text] [Related]
11. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
[TBL] [Abstract][Full Text] [Related]
12. 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
Mospan GA; Wargo KA
J Am Board Fam Med; 2016 Nov; 29(6):654-662. PubMed ID: 28076247
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis.
Bientinesi R; Murri R; Sacco E
Expert Opin Pharmacother; 2020 Apr; 21(6):637-644. PubMed ID: 32004097
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
[TBL] [Abstract][Full Text] [Related]
16. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Naber KG; Llorens L; Kaniga K; Kotey P; Hedrich D; Redman R
Antimicrob Agents Chemother; 2009 Sep; 53(9):3782-92. PubMed ID: 19581455
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
Klimberg IW; Cox CE; Fowler CL; King W; Kim SS; Callery-D'Amico S
Urology; 1998 Apr; 51(4):610-5. PubMed ID: 9586615
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial.
Vachhani AV; Barvaliya M; Naik V; Jha P; Tripathi C
Infez Med; 2015 Jun; 23(2):155-60. PubMed ID: 26110296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
